Changing Times at *CNS Neuroscience & Therapeutics*

Formerly *CNS Drug Reviews*

www.blackwellpublishing.com/CNSNT

It is an honor, privilege and indeed, challenge to take over as Editor of *CNS Neuroscience and Therapeutics*. Formerly entitled *CNS Drug Review*, this journal grew under the direction of the founding editor, Dr. Alexander Scriabine, his co-editor Dr. David Triggle and the editorial board, moving into the top third of neuroscience journals and achieving an impact factor of 3.474. They have our profound gratitude and appreciation as we seek to build on their efforts and success and move to expand the journal's scope and reach.

This issue of *CNS Neuroscience and Therapeutics* introduces a new title for the journal, which we sought to have reflect its broadened scope of emphasis. In addition to the journal's traditional interest in CNS-related drugs, we will be publishing original research papers as well as timely reviews and reports of novel findings in translational neuroscience, phenomenology and pathophysiology of psychiatric and related disorders, and pharmacologic as well as psychosocial therapeutics for psychiatric and related disorders. In addition to widening the focus of the journal, we've increased its actual physical size as well, to make it use more comfortable for the reader. While we will continue to benefit from the wisdom of many current members of the editorial board, the journal will also be invigorated by the addition of a number of new members, outstanding clinicians and scientists who will help ensure our continued focus on cutting edge science and therapeutics. The journal also benefits from an exceptional administrative team led by the managing editor, Rosanna Diogini, who adroitly keeps the journal moving forward.

This is an extraordinarily exciting period in the neurosciences as we advance our understanding of the underpinnings of psychiatric and related disorders, including neurobiology, chemistry and physiology, as well as genetics and psychological processes. The perspective of translational neuroscience linking basic and clinical research along with therapeutics in a "bench to bedside and back" paradigm holds the promise of bringing advances in cutting-edge science to inform clinical practice. We are committed to having *CNS Neuroscience and Therapeutics* help advance the field by publishing work that contributes to progress in science and ultimately enhances the care and well-being of our patients.

We will continue to endeavor to make the submission and review process efficient and timely. Our website including both guidelines for authors and access to content will be updated on an ongoing basis to enhance the accessibility of the journal. Of note, we do require that sources of funding for reported research be explicitly noted and all real or even potential conflicts of interest for each author be listed in the acknowledgment section of each paper.

This journal reflects an ongoing collaboration between the editors, reviewers, authors and readers, and as Editor I welcome the comments and suggestions of all of our stakeholders regarding ways that we may improve *CNS Neuroscience and Therapeutics* and best contribute to the sense of excitement and ongoing advancement of our field.

Mark H. Pollack